[
    [
        {
            "time": "",
            "orginal_text": "步长制药只能排第五",
            "features": {
                "keywords": [
                    "步长制药",
                    "排名",
                    "第五"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "步长制药只能排第五",
            "scores": {
                "News_content": "步长制药只能排第五",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "A股绝地反击！这些个股或成为反弹先锋？（名单）",
            "features": {
                "keywords": [
                    "A股",
                    "绝地反击",
                    "反弹先锋"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "A股绝地反击！这些个股或成为反弹先锋？（名单）",
            "scores": {
                "News_content": "A股绝地反击！这些个股或成为反弹先锋？（名单）",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "去年A股药企销售费用2500亿，研发费用仅340亿，这是行业共性吗？",
            "features": {
                "keywords": [
                    "A股",
                    "药企",
                    "销售费用",
                    "研发费用"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "去年A股药企销售费用2500亿，研发费用仅340亿，这是行业共性吗？",
            "scores": {
                "News_content": "去年A股药企销售费用2500亿，研发费用仅340亿，这是行业共性吗？",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "贝达药业单一产品占营收超过98% 如何应对带量采购？",
            "features": {
                "keywords": [
                    "贝达药业",
                    "单一产品",
                    "营收",
                    "带量采购"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "贝达药业单一产品占营收超过98% 如何应对带量采购？",
            "scores": {
                "News_content": "贝达药业单一产品占营收超过98% 如何应对带量采购？",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "融资余额回落，北上资金净流入——资金面周观察",
            "features": {
                "keywords": [
                    "融资余额",
                    "北上资金",
                    "净流入",
                    "资金面"
                ],
                "sentiment_score": 0.1,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "融资余额回落，北上资金净流入——资金面周观察",
            "scores": {
                "News_content": "融资余额回落，北上资金净流入——资金面周观察",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "小而全的恩华药业能否长大？",
            "features": {
                "keywords": [
                    "恩华药业",
                    "成长性"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "original_text": "小而全的恩华药业能否长大？",
            "scores": {
                "News_content": "小而全的恩华药业能否长大？",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "豪森2型糖尿病新药获批上市：每周一次，首个国产，对标礼来、三生",
            "features": {
                "keywords": [
                    "豪森",
                    "糖尿病",
                    "新药",
                    "国产",
                    "礼来",
                    "三生"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "豪森2型糖尿病新药获批上市：每周一次，首个国产，对标礼来、三生",
            "scores": {
                "News_content": "豪森2型糖尿病新药获批上市：每周一次，首个国产，对标礼来、三生",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "717亿资金争夺20股：主力资金重点出击7股(名单)",
            "features": {
                "keywords": [
                    "资金",
                    "主力资金",
                    "出击",
                    "名单"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "717亿资金争夺20股：主力资金重点出击7股(名单)",
            "scores": {
                "News_content": "717亿资金争夺20股：主力资金重点出击7股(名单)",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "[异动股]超级真菌板块拉升，神奇制药(600613-CN)涨停",
            "features": {
                "keywords": [
                    "异动股",
                    "超级真菌",
                    "神奇制药",
                    "涨停"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "[异动股]超级真菌板块拉升，神奇制药(600613-CN)涨停",
            "scores": {
                "News_content": "[异动股]超级真菌板块拉升，神奇制药(600613-CN)涨停",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "西南证券：全年医药行业收入端整体或维持约10%增长",
            "features": {
                "keywords": [
                    "西南证券",
                    "医药行业",
                    "收入增长"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "西南证券：全年医药行业收入端整体或维持约10%增长",
            "scores": {
                "News_content": "西南证券：全年医药行业收入端整体或维持约10%增长",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "专家：打压现货、做空期指获利的论调可以休矣",
            "features": {
                "keywords": [
                    "专家",
                    "现货",
                    "期指",
                    "获利"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "专家：打压现货、做空期指获利的论调可以休矣",
            "scores": {
                "News_content": "专家：打压现货、做空期指获利的论调可以休矣",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "生物制药公司 加大研发投入成趋势",
            "features": {
                "keywords": [
                    "生物制药",
                    "研发投入",
                    "趋势"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "生物制药公司 加大研发投入成趋势",
            "scores": {
                "News_content": "生物制药公司 加大研发投入成趋势",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "orginal_text": "MSCI纳入因子提升在即 或引300亿元增量资金",
            "features": {
                "keywords": [
                    "MSCI",
                    "纳入因子",
                    "增量资金"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "MSCI纳入因子提升在即 或引300亿元增量资金",
            "scores": {
                "News_content": "MSCI纳入因子提升在即 或引300亿元增量资金",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "2018年仅25家上市药企亏损 医药行业整体承压",
            "features": {
                "keywords": [
                    "2018年",
                    "上市药企",
                    "亏损",
                    "医药行业",
                    "承压"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "2018年仅25家上市药企亏损 医药行业整体承压",
            "scores": {
                "News_content": "2018年仅25家上市药企亏损 医药行业整体承压",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]